knowledge -WSS

knowledge

author：explore 2025-09-30 18:59:38 - browse：93

The Food and Drug Administration on Tuesday approved brexanolone, the first drug specifically targeted to treat postpartum depression — the most common complication of childbirth. Yet it’s a condition that often goes untreated because new mothers fear being stigmatized if they report symptoms.

Brexanolone is the first drug developed by and approved from Sage Therapeutics. The Cambridge, Mass.-based biotech company will market the new medicine under the brand name Zulresso.

“This approval is important for postpartum depression patients and it’s important for our company. It’s rare in your career when you can introduce a new medicine that is different from what’s out there,” said Sage CEO Jeff Jonas.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Bacterial infection may be ‘key event’ in endometriosis, study says

WSS

The stability of $0 premiums in Medicare Advantage

CDC picks Alphabet's Verily for wasterwater surveillance contract

Setback for rare diseases as Taysha Gene Therapies pulls back

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Health insurers' Q3 question: how much care are people getting?

2023 Nobel Prize in Medicine goes to Karikó and Weissman

entertainment

knowledge

leisure time

In age of alternative facts, a scholarly course on calling out crap

Flu, Covid vaccination rates decline, new survey data show

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Did the public have the right to know Arthur Ashe had AIDS?

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Did the public have the right to know Arthur Ashe had AIDS?

Medical leaders decry Supreme Court decision on affirmative action

6 solutions to address cancer drug shortages and others

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Meta looks to target Twitter with a rival app called Threads

leisure time

Some top drug companies are starting to take action on climate

The stability of $0 premiums in Medicare Advantage

6 solutions to address cancer drug shortages and others

Setback for rare diseases as Taysha Gene Therapies pulls back

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

explore

hotspot

leisure time

entertainment